In addition, PD1/PD-L1 checkpoint blockade is regulated by YTHDF1 (m6A reader) and FTO (eraser), and m6A modulators may be potential anti-cancer immunotherapy targets (Yang S. et al., 2019; Han et al., 2019). The gene discussed is CD274; the disease is cancer.